Short Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Rises By 12.5%

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 6,680,000 shares, a growth of 12.5% from the December 31st total of 5,940,000 shares. Based on an average daily volume of 975,100 shares, the days-to-cover ratio is presently 6.9 days.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of the business's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Steve Miller sold 50,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now owns 686,996 shares of the company's stock, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $27,000. GAMMA Investing LLC lifted its holdings in Catalyst Pharmaceuticals by 62.1% during the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 681 shares during the period. nVerses Capital LLC purchased a new position in Catalyst Pharmaceuticals in the third quarter worth $50,000. Larson Financial Group LLC grew its stake in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 2,994 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $65,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on CPRX shares. Stephens began coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an "overweight" rating and a $35.00 target price for the company. HC Wainwright increased their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, January 10th. Robert W. Baird assumed coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday. They set an "outperform" rating and a $28.00 target price on the stock. Truist Financial increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. Finally, Bank of America reaffirmed a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of "Buy" and an average target price of $32.25.

Catalyst Pharmaceuticals Trading Down 0.7 %

NASDAQ CPRX traded down $0.16 during trading hours on Friday, hitting $22.90. The company's stock had a trading volume of 592,176 shares, compared to its average volume of 1,371,444. The company has a market capitalization of $2.73 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 2.25 and a beta of 0.80. Catalyst Pharmaceuticals has a 52 week low of $13.12 and a 52 week high of $24.64. The company's 50-day simple moving average is $22.07 and its two-hundred day simple moving average is $20.87.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.